Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated japanese lung cancer patients

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Nyberg, Fredrik ^a,b   Ogiwara, Atsushi ^c,d   Harbron, Chris G ^e   Kawakami, Takao ^c,d   Nagasaka, Keiko ^c   Takami, Sachiko ^c   Wada, Kazuya ^c   Tu, Hsiao Kun ^c   Otsuji, Makiko ^c   Kyono, Yutaka ^c   Dobashi, Tae ^c   Komatsu, Yasuhiko ^c   Kihara, Makoto ^c   Akimoto, Shingo ^c,d   Peers, Ian S ^e   South, Marie C ^e   Higenbottam, Tim ^a,l   Fukuoka, Masahiro ^f   Nakata, Koichiro ^g   Ohe, Yuichiro ^h   Kudoh, Shoji ^i,j   Clausen, Ib Groth ^a   Nishimura, Toshihide ^c,d   Marko Varga, György ^a,d,m   Kato, Harubumi ^d,k   more..

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Medical ProteoScope Company   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e ASTRAZENECA   (United Kingdom)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Nakata Clinic   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

ⁱ Japan Anti Tuberculosis Association   (Japan)

^j NIPPON MEDICAL SCHOOL   (Japan)

^k Division of Dermatology   (Japan)

^l CHIESI FARMACEUTICI S P A   (Italy)

^m LUND UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ACID GLYCOPROTEIN 1; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 1B GLYCOPROTEIN; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; ARMADILLO REPEAT CONTAINING PROTEIN 2; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4 A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C9; FETUIN A; GEFITINIB; GELSOLIN; HAPTOGLOBIN; HAPTOGLOBIN RELATED PROTEIN; HEMOGLOBIN A; HEMOGLOBIN D; IMMUNOGLOBULIN KAPPA CHAIN; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; PLASMA KALLIKREIN; PREALBUMIN; RETINOL BINDING PROTEIN 4; SERUM AMYLOID P; TRANSFERRIN; UNCLASSIFIED DRUG; PEPTIDE; QUINAZOLINE DERIVATIVE;

ACUTE DISEASE; ADVANCED CANCER; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FUNCTIONAL PROTEOMICS; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; PEPTIDE ANALYSIS; PHENOTYPIC VARIATION; PREDICTIVE VALUE; PROTEIN EXPRESSION; RISK ASSESSMENT; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; WESTERN BLOTTING; ASIAN; BLOOD; DISCRIMINANT ANALYSIS; ISOLATION AND PURIFICATION; LUNG TUMOR; METHODOLOGY; PHENOTYPE; PROTEIN DATABASE; PROTEOMICS; QUALITY CONTROL; REPRODUCIBILITY;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, LIQUID; DATABASES, PROTEIN; DISCRIMINANT ANALYSIS; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; PEPTIDES; PHENOTYPE; PROTEOMICS; QUALITY CONTROL; QUINAZOLINES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 79960608581     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022062     Document Type: Article

References (45)

1. American Thoracic Society, European Respiratory Society (2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165: 277-304.
2. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, et al. (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139.
3. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, et al. (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177: 1348-1357.
4. Wells AU, Hogaboam CM, (2007) Update in diffuse parenchymal lung disease 2006. Am J Respir Crit Care Med 175: 655-660.
5. Raghu G, Nyberg F, Morgan G, (2004) The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91 (Suppl 2): S3-S10.
6. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, et al. (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24: 3657-3663.
7. Abid SH, Malhotra V, Perry MC, (2001) Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 13: 242-248.
8. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, et al. (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24: 2549-2556.
9. Danson S, Blackhall F, Hulse P, Ranson M, (2005) Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 28: 103-113.
10. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC, (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20: 1245-1259.
11. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, et al. (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18: 122-130.
12. Azuma A, Kudoh S, (2007) High prevalence of drug-induced pneumonia in Japan. JMAJ 50: 405-411.
13. Koo L, Clark J, Quesenberry CP, Higenbottam T, Nyberg F, et al. (2005) National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO drug monitoring database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf 14: 775-787.
14. Marko-Varga G, Ogiwara A, Nishimura T, Kawamura T, Fujii K, et al. (2007) Personalized medicine and proteomics: lessons from non-small cell lung cancer. J Proteome Res 6: 2925-2935.
15. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, et al. (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3: 311-326.
16. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, et al. (2003) The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 3: 1345-1364.
17. McDonald WH, Yates JR, III, (2003) Shotgun proteomics: integrating technologies to answer biological questions. Curr Opin Mol Ther 5: 302-309.
18. America AH, Cordewener JH, (2008) Comparative LC-MS: a landscape of peaks and valleys. Proteomics 8: 731-749.
19. Gygi SP, Rochon Y, Franza BR, Aebersold R, (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720-1730.
20. Oda Y, Huang K, Cross FR, Cowburn D, Chait BT, (1999) Accurate quantitation of protein expression and site-specific phosphorylation. Proc Natl Acad Sci U S A 96: 6591-6596.
21. Ong SE, Mann M, (2005) Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 1: 252-262.
22. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, et al. (2005) Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 4: 1265-1272.
23. Rappsilber J, Ryder U, Lamond AI, Mann M, (2002) Large-scale proteomic analysis of the human spliceosome. Genome Res 12: 1231-1245.
24. Brancia FL, (2006) Recent developments in ion-trap mass spectrometry and related technologies. Expert Rev Proteomics 3: 143-151.
25. Schwartz JC, Senko MW, Syka JE, (2002) A two-dimensional quadrupole ion trap mass spectrometer. J Am Soc Mass Spectrom 13: 659-669.
26. Silliman CC, McLaughlin NJ, (2006) Transfusion-related acute lung injury. Blood Rev 20: 139-159.
27. Fontana V, Horstman LL, Donna E, Dudkiewicz P, Ahn ER, et al. (2007) Interstitial lung disease (ILD) and severe ITP. Hematology 12: 75-80.
28. Huang YC, Bassett MA, Levin D, Montilla T, Ghio AJ, (2006) Acute phase reaction in healthy volunteers after bronchoscopy with lavage. Chest 129: 1565-1569.
29. Shi W, Xu J, Warburton D, (2009) Development, repair and fibrosis: what is common and why it matters. Respirology 14: 656-665.
30. Oikonomou N, Thanasopoulou A, Tzouvelekis A, Harokopos V, Paparountas T, et al. (2009) Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis. Thorax 64: 467-475.
31. Isshiki H, Akira S, Sugita T, Nishio Y, Hashimoto S, et al. (1991) Reciprocal expression of NF-IL6 and C/EBP in hepatocytes: possible involvement of NF-IL6 in acute phase protein gene expression. New Biol 3: 63-70.
32. Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P, (1993) The role of NF-kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 268: 25624-25631.
33. Cook NR, Ridker PM, (2009) Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 150: 795-802.
34. Seferovic MD, Krughkov V, Pinto D, Han VK, Gupta MB, (2008) Quantitative 2-D gel electrophoresis-based expression proteomics of albumin and IgG immunodepleted plasma. J Chromatogr B Analyt Technol Biomed Life Sci 865: 147-152.
35. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (2010) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275.
36. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
37. Pravdova V, Walczak B, Massart DL, (2002) A comparison of two algorithms for warping of analytical signals. Anal Chim Acta 456: 77-92.
38. Nielsen N-PV, Carstensen JM, Smedsgaard J, (1998) Aligning of single and multiple wavelength chromatographic profiles. J Chromatogr A 805: 17-35.
39. Listgarten J, Emili A, (2005) Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 4: 419-434.
40. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M, (2002) Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 (Suppl 1): S96-104.
41. Joliffe IT, (1980) Principal Component Analysis. New York Springer.
42. Geladi P, Kowalski B, (1986) Partial least-squares regression: a tutorial. Anal Chim Acta 185: 1-17.
43. Dupuy A, Simon RM, (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99: 147-157.
44. Breiman L, (2001) Random Forests. Machine Learning 45: 5-32.
45. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS, (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20: 3551-3567.